Table 4.

Characteristics of patients with AML responding to cytarabine/SCH 900776 combination

Dose levelAge/sexDisease statusNo. of prior regimen/cytarabineaPrior SCTCytogeneticsResponse (CR/CRi)SCT or DLIDFS (mo)
149 MRefb4/++46XYCRiSCT2.0
352 F10 Refb1/−45XX, −5q, −7, +19qCR2.2
355 M10 Refb1/+46XY, +20qCRSCT11.3
325 MRelapse 7 moc4/++46XY, t(8;21), −9qCR25.2+
470 M10 Refb1/+46XYCR9.7
460 MRelapse 8 mo4/++46XYCRDLI22.4+
573 MRelapse 66 mod2/+46XYCRi0.2
561 FRelapse 19 mo2/+46XX, inv (16), +22CRSCT18.1+
  • aCytarabine, 2 g/m2/72 hours infusion or high dose.

  • bRef, refractory.

  • cCR duration before beginning cytarabine/SCH900776.

  • dPossible new AML rather than relapse, refractory to reinduction.